What are the reasons for the repeated failures of clinical trials with anti-amyloid drugs for AD treatment?

Documenti analoghi

• Subtherapeutic dose lithium treatment induces behavioral and neuropathological changes in 3xTg‐AD Alzheimer's mice
  di: Monique Patricio Singulani, et al.
  Pubblicazione: (2025)
• Dose‐Dependent Effects of Lithium on Biological Pathways, Ribosomes, Mitochondria, and Proteasomes in Hippocampal Neurons: Insights from Gene and Protein Expression
  di: Orestes Vicente Forlenza, et al.
  Pubblicazione: (2025)
• Phosphatidylcholine as a potential AD‐related biomarker in Down syndrome, but not in Alzheimer's disease patients: Preliminary findings
  di: Bruna Berribilli Bortoleto, et al.
  Pubblicazione: (2025)
• Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid drugs in Alzheimer's disease: a Bayesian meta-analysis
  di: Ren, Sa, et al.
  Pubblicazione: (2025)
• What are the recommended first-line anti-resorptive drugs for the treatment of osteoporosis according to the latest clinical guidelines?
  di: Tripdatabase
  Pubblicazione: (2026)